Overview

Anti-Inflammatory Treatment of Uremic Cardiomyopathy With Colchicine

Status:
Not yet recruiting
Trial end date:
2025-11-11
Target enrollment:
Participant gender:
Summary
This study is designed to determine the efficacy and safety of colchicine in patients with chronic kidney disease.
Phase:
Phase 2
Details
Lead Sponsor:
Brigham and Women's Hospital
Collaborator:
National Heart, Lung, and Blood Institute (NHLBI)
Treatments:
Colchicine